Redmile Group, LLC - Insider Trading & Ownership

Location
One Letterman Drive, Building D, Suite D3 300, San Francisco, CA
Summary
The estimated value of insider holdings of Redmile Group, LLC is at least $699M dollars as of October 28, 2025. Redmile Group, LLC is the Director, 10%+ Owner of MedAvail Holdings, Inc. and owns shares of MedAvail Holdings, Inc. stock worth about $331M. Redmile Group, LLC is the 10%+ Owner of ADC Therapeutics SA and owns shares of ADC Therapeutics SA (ADCT) stock worth about $140M. Redmile Group, LLC is the Director, 10%+ Owner of FATE THERAPEUTICS INC and owns shares of FATE THERAPEUTICS INC (FATE) stock worth about $45.7M. Redmile Group, LLC is the Director of Absci Corp and owns shares of Absci Corp (ABSI) stock worth about $41.1M. Redmile Group, LLC is the 10%+ Owner of RayzeBio, Inc. and owns shares of RayzeBio, Inc. stock worth about $33.4M. Redmile Group, LLC is the 10%+ Owner of Entrada Therapeutics, Inc. and owns shares of Entrada Therapeutics, Inc. (TRDA) stock worth about $31.3M. Redmile Group, LLC is the 10%+ Owner of Zymeworks Inc. and owns shares of Zymeworks Inc. (ZYME) stock worth about $30.6M. Redmile Group, LLC is the 10%+ Owner of Verve Therapeutics, Inc. and owns shares of Verve Therapeutics, Inc. (VERV) stock worth about $19.4M. Redmile Group, LLC is the 10%+ Owner of Adagio Therapeutics, Inc. and owns shares of Invivyd, Inc. (IVVD) stock worth about $13.4M. Redmile Group, LLC is the Director, 10%+ Owner of Shattuck Labs, Inc. and owns shares of Shattuck Labs, Inc. (STTK) stock worth about $6.92M. Redmile Group, LLC is the Director, 10%+ Owner of IGM Biosciences, Inc. and owns shares of IGM Biosciences, Inc. (IGMS) stock worth about $3.53M. Redmile Group, LLC is the Director of Atara Biotherapeutics, Inc. and owns shares of Atara Biotherapeutics, Inc. (ATRA) stock worth about $3.36M.
Signature
By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
All Insider Reports
All Insider Reports

Ownership of Redmile Group, LLC

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
MDVL MedAvail Holdings, Inc. Director, 10%+ Owner $331M Jun 16, 2023
ADCT ADC Therapeutics SA 10%+ Owner $140M +$127M +1024% Oct 27, 2025
FATE FATE THERAPEUTICS INC Director, 10%+ Owner $45.7M +$94.6K +0.21% May 29, 2025
ABSI Absci Corp Director $41.1M Jun 12, 2024
RYZB RayzeBio, Inc. 10%+ Owner $33.4M Sep 19, 2023
TRDA Entrada Therapeutics, Inc. 10%+ Owner $31.3M Nov 2, 2021
ZYME Zymeworks Inc. 10%+ Owner $30.6M Oct 13, 2022
VERV Verve Therapeutics, Inc. 10%+ Owner $19.4M Jun 21, 2021
IVVD Invivyd, Inc. 10%+ Owner $13.4M Aug 10, 2021
STTK Shattuck Labs, Inc. Director, 10%+ Owner $6.92M $0 0% Aug 25, 2025
IGMS IGM Biosciences, Inc. Director, 10%+ Owner $3.53M Aug 14, 2025
ATRA Atara Biotherapeutics, Inc. Director $3.36M May 16, 2025
AUGX Augmedix, Inc. Director, 10%+ Owner $0 Oct 2, 2024
SNCE Science 37 Holdings, Inc. Former 10% Owner and Director $0 Mar 12, 2024

Insider Transactions Reported by Redmile Group, LLC:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.